Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Go back to Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 79.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.17 | 52 Week High | $13.18 | |||
| Open | $79.17 | 52 Week Low | $6.00 | |||
| Day High | $79.17 | P/E | N/A | |||
| Day Low | $79.17 | EPS | $-1.24 | |||
| Volume | 405 | |||||
